| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ... Science 350 (6257), 207-211, 2015 | 3157 | 2015 |
| Improved survival with MEK inhibition in BRAF-mutated melanoma KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ... New England Journal of Medicine 367 (2), 107-114, 2012 | 2801 | 2012 |
| Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer U Sahin, E Derhovanessian, M Miller, BP Kloke, P Simon, M Löwer, ... Nature 547 (7662), 222-226, 2017 | 2799 | 2017 |
| Induced pluripotent stem cells generated without viral integration M Stadtfeld, M Nagaya, J Utikal, G Weir, K Hochedlinger Science 322 (5903), 945-949, 2008 | 2393 | 2008 |
| Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution N Maherali, R Sridharan, W Xie, J Utikal, S Eminli, K Arnold, M Stadtfeld, ... Cell stem cell 1 (1), 55-70, 2007 | 2308 | 2007 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 2266 | 2014 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1738 | 2015 |
| Immortalization eliminates a roadblock during cellular reprogramming into iPS cells J Utikal, JM Polo, M Stadtfeld, N Maherali, W Kulalert, RM Walsh, A Khalil, ... Nature 460 (7259), 1145-1148, 2009 | 1097 | 2009 |
| An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma U Sahin, P Oehm, E Derhovanessian, RA Jabulowsky, M Vormehr, ... Nature 585 (7823), 107-112, 2020 | 1054 | 2020 |
| Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Arnon, ... Nature medicine 25 (12), 1916-1927, 2019 | 974 | 2019 |
| Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression C Groth, X Hu, R Weber, V Fleming, P Altevogt, J Utikal, V Umansky British journal of cancer 120 (1), 16-25, 2019 | 893 | 2019 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639, 2017 | 849 | 2017 |
| A high-efficiency system for the generation and study of human induced pluripotent stem cells N Maherali, T Ahfeldt, A Rigamonti, J Utikal, C Cowan, K Hochedlinger Cell stem cell 3 (3), 340-345, 2008 | 783 | 2008 |
| Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, ... European journal of cancer 60, 190-209, 2016 | 757 | 2016 |
| Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task TJ Brinker, A Hekler, AH Enk, J Klode, A Hauschild, C Berking, B Schilling, ... European Journal of Cancer 113, 47-54, 2019 | 683 | 2019 |
| Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy L Zimmer, SM Goldinger, L Hofmann, C Loquai, S Ugurel, I Thomas, ... European journal of cancer 60, 210-225, 2016 | 635 | 2016 |
| Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors R Weber, V Fleming, X Hu, V Nagibin, C Groth, P Altevogt, J Utikal, ... Frontiers in immunology 9, 1310, 2018 | 592 | 2018 |
| Skin cancer classification using convolutional neural networks: systematic review TJ Brinker, A Hekler, JS Utikal, N Grabe, D Schadendorf, J Klode, ... Journal of medical Internet research 20 (10), e11936, 2018 | 588 | 2018 |
| The role of myeloid-derived suppressor cells (MDSC) in cancer progression V Umansky, C Blattner, C Gebhardt, J Utikal Vaccines 4 (4), 36, 2016 | 521 | 2016 |
| Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression V Fleming, X Hu, R Weber, V Nagibin, C Groth, P Altevogt, J Utikal, ... Frontiers in immunology 9, 398, 2018 | 515 | 2018 |
Dirk SchadendorfProfessor für Dermatologie, University Hospital Essen; University of Duisburg-EssenVerified email at uk-essen.de
